phase 3 clinical trial

Efficacy and Safety of Ecopipam for Tourette Syndrome: Phase 3 Randomized Clinical Trial

This phase 3 trial found that ecopipam reduced tic relapse and maintained symptom improvement in children and adolescents with Tourette syndrome, with mainly central nervous system side effects and no major weight or metabolic concerns.